Editors' ChoiceMEDICINE

Papers of note in Science Translational Medicine 9 (407)

See allHide authors and affiliations

Sci. Signal.  19 Sep 2017:
Vol. 10, Issue 497, eaap9132
DOI: 10.1126/scisignal.aap9132

This week’s articles show that blocking a prometastatic process unintentionally impairs immunotherapy and report new therapeutic targets in type 2 diabetes and asthmatic lung disease.

CANCER

Unintentional interference

Fankhauser et al. found that the the lymphangiogenic growth factor VEGF-C enhanced the response to immune checkpoint inhibitors by recruiting naïve T cells into the tumor, indicating that clinical efforts to block lymphangiogenic signals through VEGF-C receptors may unintentionally impede immunotherapeutic efficacy.

METABOLIC DISEASE

An apelin a day keeps the doctor away

Hwangbo et al. report that inhibition of fatty acid binding protein 4 (FABP4) rescues defective apelin signaling, decreases fatty acid accumulation, and promotes insulin sensitivity.

ASTHMA

Breathing freely

Matthey et al. identified the compound FR900359 as a selective Gq inhibitor that when inhaled by mouse models of allergen-induced asthma promoted airway relaxation without the cardiovascular side effects associated with currently prescribed inhalants.

Highlighted Articles

View Abstract

Navigate This Article